Hypoactive Sexual Desire Disorder Treatment Market

Market Overview:

The global hypoactive sexual desire disorder treatment market size reached US$ 2.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.1 Billion by 2028, exhibiting a growth rate (CAGR) of 4.8% during 2023-2028.

Hypoactive sexual desire disorder (HSDD) refers to a medical condition with low libido or sexual desire in women. The sexual dysfunction in HSDD is primarily associated with hyperfunction inhibition and hypofunctional excitation regulated by neuromodulators in the brain. Furthermore, several physical conditions are also related to HSDD, including anxiety, depression, diabetes, urinary incontinence, menopause, multiple sclerosis, etc. HSDD treatment mainly includes psychotherapy or pharmacotherapy. Psychotherapy utilizes cognitive behavioral therapy, which offers counseling sessions with a sex therapist, whereas pharmacotherapy comprises of treatment with several drugs, such as Buspirone, Bupropion, Testosterone, Flibanserin, etc.

The rising working women population coupled with their hectic work schedules often result in low libido conditions, thereby augmenting the demand for HSDD treatment. Furthermore, the high prevalence of numerous lifestyle ailments, such as anxiety, stress, depression, prolonged fatigue, irregular menstruation, etc., is also catalyzing the incidences of HSDD. Additionally, diminished libido can also be a side-effect of certain chemical-based drugs that may further lead imbalance of neurotransmitters in the brain, causing HSDD. Moreover, the rising aging women population, premature menopause, and low self-esteem towards one’s physical appearance is also associated with low libido in women, thereby driving the demand for HSDD treatment. Besides this, the reducing stigma associated with HSDD coupled with the growing awareness towards the disease diagnosis and effective treatment is further propelling the market growth. The emergence of the PLISSIT model (Permission, Limited Information, Specific Suggestions, and Intensive Therapy) aids in the initial screening of HSDD. Furthermore, the faster drug approvals for treating HSDD along with the increasing investments in new drug development activities are further catalyzing the market growth. For instance, the U.S. Food and Drug Administration (FDA) approved ‘Vyleesi’ that activates melanocortin receptors for improving sexual desire in women.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hypoactive sexual desire disorder treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapy, distribution channel and application.

Breakup by Therapy:

• Buspirone
• Bupropion
• Testosterone
• Flibanserin
• Bremelanotide
• Cognitive Behavior Therapy 
   

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
   

Breakup by Application:

• Hospitals
• Clinics
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Others
• Middle East and Africa
  • Saudi Arabia
  • Iran
  • Turkey
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
     

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Allergan Plc, AMAG Pharmaceuticals, Inc., Emotional Brain BV, Endoceutics, Inc., GlaxoSmithKline Plc, Ovoca Bio Plc, Pivot Pharmaceuticals, Inc., Palatin Technologies, Inc., S1 Biopharma, Inc., and Sprout Pharmaceuticals, Inc.

Report Coverage: